Biomira, Inno-centre deal

BRA and Inno-centre spun out Oncodigm BioPharma Inc., which will develop and commercialize BRA's liposomal interleukin-2 (L-IL-2). Oncodigm will be owned 90% by BRA and 10% by Inno-centre, a private...